Skip to main content
. 2024 May 27;25(11):5817. doi: 10.3390/ijms25115817

Figure 2.

Figure 2

Epithelial barrier function in HC and IBD patients before and after 24 weeks and 52 weeks of treatment with vedolizumab (VDZ). Transepithelial electrical resistance (TEER) at the time points 30, 60, 90 and 120 min (A), and as the average over 30–120 min (B). Paracellular passage of FD4 at the time points 30, 60, 90 and 120 min (C), and as the average over 60–120 min (D). Data are mean ± standard deviation (SD). In (A–D): n = 26 healthy controls, n = 22 IBD patients at baseline, n = 18 IBD patients after 24 weeks of VDZ treatment, n = 12 IBD patients after 52 weeks of VDZ treatment. One-way ANOVA in (B,D) followed by Dunn’s multiple comparisons test, and two-way ANOVA in (A,C) followed by Sidak’s multiple comparisons test. ** p < 0.01 vs. healthy controls, *** p < 0.001 vs. healthy controls.